Canakinumab in Covid-19 Cardiac Injury (The Three C Study)

Completed · Phase 2 · Has a placebo group

Conditions studied: COVID-19, SARS-CoV 2

In brief

TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in patients with COVID-19 infection. These results will lead to and inform a Phase III randomized placebo-controlled trial.

Key facts

Study ID

NCT04365153

Run by

The Cleveland Clinic

People needed

45

Starts

2020-04-24

Expected to finish

2021-04-01

Last updated by the study team

2021-04-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Cleveland Clinic Florida — Weston, Florida, United States
• Cleveland Clinic — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.